Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-150 for pain caused by small fiber neuropathy
NL-OMON46746Phase 2Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in small fiber neuropathy (SFN) comparing VX-150 with Placebo (2 arms). Primary endpoint: Change from baseline in weekly average daily pain intensity at Week 6. Started Mar 2018; status: active, not recruiting.
02
Drugs
VX-150
03
Conditions
small fiber neuropathy (SFN)
Beyond the preview
Go deeper on NL-OMON46746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46746.